RxDoctor Payments Data

Kari Mathison, MD

Family Medicine · Santa Barbara, CANPI 1124124276

Payments from drug & device makers

$2,073in general payments, 2019–2025

Across 85 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$738
  • Novo Nordisk$256
  • GSK$184
  • Johnson & Johnson$173
  • AbbVie$136
  • Dexcom, Inc.$125
  • plus $461 from 11 others

What the payments were for

  • Food & beverage$2,05399%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,073 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$89,090
Medicare patients
256
Services billed
862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol34$53,455
EliquisApixaban48$51,782
OzempicSemaglutide28$26,110
XareltoRivaroxaban12$18,488
Rosuvastatin Calcium232$5,034
Atorvastatin Calcium357$3,916
SynthroidLevothyroxine Sodium40$3,476
SymbicortBudesonide/Formoterol Fumarate12$3,262
Metoprolol Succinate149$2,497
Diltiazem 24hr Er (Cd)Diltiazem Hcl33$2,419
Levothyroxine Sodium173$2,377
Losartan Potassium207$2,344
Ezetimibe60$2,117
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide56$1,343
ValacyclovirValacyclovir Hcl26$1,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$738$56,71746 claims
PfizerEliquis$119$51,78248 claims
Novo NordiskOzempic$256$26,11028 claims
Johnson & JohnsonXarelto$173$18,48812 claims
AbbVieSynthroid$136$3,47640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →